Cargando…
Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis
BACKGROUND: The objective of this study was to evaluate the efficacy and safety of repeated low-dose rituximab treatment guided by monitoring circulating CD19+ B cells in patients with refractory myasthenia gravis (MG). METHODS: Patients with refractory MG who had received rituximab treatment at two...
Autores principales: | Choi, Kyomin, Hong, Yoon-Ho, Ahn, So-Hyun, Baek, Seol-Hee, Kim, Jun-Soon, Shin, Je-Young, Sung, Jung-Joon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751534/ https://www.ncbi.nlm.nih.gov/pubmed/31555344 http://dx.doi.org/10.1177/1756286419871187 |
Ejemplares similares
-
Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2016) -
Rituximab treatment in myasthenia gravis
por: Vesperinas-Castro, Ana, et al.
Publicado: (2023) -
Refractory Myasthenia Gravis Treated Successfully with Rituximab: A Case Report
por: Rahul, L Yadav, et al.
Publicado: (2017) -
Rituximab in Refractory Myasthenia Gravis: Experience in a Single Healthcare Center in Mexico
por: López-Hernández, Juan Carlos, et al.
Publicado: (2021) -
Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis
por: Verma, Neha, et al.
Publicado: (2021)